85. Idiopathic interstitial pneumonia Clinical trials / Disease details
Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05389215 (ClinicalTrials.gov) | July 29, 2022 | 17/4/2022 | Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: DWN12088;Drug: Placebo | Daewoong Pharmaceutical Co. LTD. | NULL | Recruiting | 40 Years | N/A | All | 102 | Phase 2 | United States;Korea, Republic of |
2 | NCT04888715 (ClinicalTrials.gov) | July 23, 2021 | 28/4/2021 | To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers | An Open Label, 2-part, One-sequence, 3-period Study to Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers | Idiopathic Pulmonary Fibrosis | Drug: DWN12088;Drug: Pirfenidone;Drug: Nintedanib | Daewoong Pharmaceutical Co. LTD. | NULL | Completed | 19 Years | 55 Years | All | 48 | Phase 1 | Korea, Republic of |
3 | NCT04888728 (ClinicalTrials.gov) | June 30, 2021 | 28/4/2021 | To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers | An Open Label, 2-part, One-sequence, 3-period Study to Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Male Volunteers | Idiopathic Pulmonary Fibrosis | Drug: DWN12088;Drug: Nebivolol;Drug: Paroxetine | Daewoong Pharmaceutical Co. LTD. | NULL | Completed | 20 Years | 55 Years | Male | 24 | Phase 1 | Korea, Republic of |
4 | NCT04767815 (ClinicalTrials.gov) | March 22, 2021 | 15/2/2021 | To Evaluate Food Effect on the PK and Safety After Oral DWN12088 Administration in Healthy Adult Volunteers | A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics and Safety After Oral DWN12088 Administration in Healthy Adult Volunteers | Idiopathic Pulmonary Fibrosis | Drug: Diet A group;Drug: Diet B group;Drug: Diet C group | Daewoong Pharmaceutical Co. LTD. | NULL | Completed | 19 Years | 55 Years | All | 36 | Phase 1 | Korea, Republic of |